Seattle, WA · Founded 2019 · Privately Held (backing)
Operator of a biotechnology platform designed to advance a novel approach to cancer immunotherapy by generating engineered immune cells. Umoja Biopharma is based in Seattle, WA and was founded in 2019. It is valued at about $509 million as of Oct 2026, set by institutional fund marks, up 21% since its later-stage round in Jan 2025. It has raised $371 million across 1 recorded round; the latest was a $210 million later-stage round in Jun 2021.
PMV mark · valuation
$508.8M
Oct 2026
Since last round
+21%
Jan 2025
Total raised
$371.0M
Last round
Later Stage VC
Jun 2021
No prints on record
No secondary trades in Umoja Biopharma shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Umoja Biopharma stock.
